dpp 4 inhibitors and glp 1 dpp-4_inhibitors [TUSOM Pharmacology, Physiology, and Mechanisms of

Adjunctive basal GLP-1-RA therapy in patients after MBS may be a promising treatment choice in weight management in addition to lifestyle changes, not only due to increased GLP-1 signaling, but also to a putative blunting effect on metabolic adaptation that occurs after MBS, increased fat oxidation, and decreased carbohydrate and protein oxidation

A board-certified clinician reviews it, with a telemed visit if more information is needed

Advances in metabolic research have positioned glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a promising therapeutic option for MASH, extending their use beyond diabetes and obesity management

In this months newsletter, Clinical Research Associate Joe Bonner, PhD will briefly review how this can happen and the importance of tracking skeletal muscle mass during weight loss